Targets › DNMT3A
7 programs from 6 companies in 260 trials: 146 Phase 2, 98 Phase 1, 11 Phase 3, 5 Phase 4; Oncology, Hematology, Neurology; next expected readout Dec 2026.
DNA (cytosine-5)-methyltransferase that mediates genome-wide de novo methylation and which is essential for the establishment of DNA methylation patterns during development. It modifies DNA in a non-processive manner and methylates both CpG and non-CpG sites. (UniProt, Q9Y6K1)
Open in Phaseline: the race on DNMT3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Azacitidine DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 4 | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) | Jul 2027 |
| National Cancer Institute (NCI) | Guadecitabine DNA methyltransferase (DNMT) inhibitor | DNMT1, DNMT3A, DNMT3B | Phase 2 | Locally Advanced Unresectable Primary Central Chondrosarcoma | Jan 2027 |
| Taiho Oncology | Azacitidine (ASTX030) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 2 | Myelodysplastic Syndromes | Nov 2027 |
| Bristol-Myers Squibb | Azacitidine (BMS-986345) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 2 | Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Angioimmunoblastic T-cell Lymphoma (AITL) … | Jul 2028 |
| Taiho Oncology | Decitabine (ASTX727) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| University of Southern California | Guadecitabine DNMT inhibitor | DNMT1, DNMT3A, DNMT3B | Phase 1 | Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Chronic Myelomonocytic Leukemia | Dec 2026 |
| EpiDestiny | Decitabine DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 1 | Sickle Cell Disease; Multiple Sclerosis; Allogeneic Hematopoietic Stem Cell Transplantation (HSCT); AML (Acute Myeloid Leukemia) … | Oct 2028 |
Acute Myeloid Leukemia (71) Myelodysplastic Syndromes (13) AML (7) Chronic Myelomonocytic Leukemia (6) Leukemia, Myeloid, Acute (5) Acute Myeloid Leukemia (AML) (5) Solid Tumor (5) T-cell Acute Lymphoblastic Leukemia (4) Myeloid Malignancy (4) AML, Adult (4) Sickle Cell Disease (3) Hairy Cell Leukemia (3)
small molecule (6), mixed (1)
Taiho Oncology (2) University of Southern California (1) EpiDestiny (1) AbbVie (1) National Cancer Institute (NCI) (1) Bristol-Myers Squibb (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.